Merit Medical (NASDAQ: MMSI) will release first quarter 2026 financial results after market close on Thursday, April 30, 2026. The company will hold an investor conference call the same day at 4:30 p.m. ET with a live webcast and slide deck available online.
Investors may pre-register for dial-in details; registration and webcast links will be posted at www.merit.com. Merit develops and distributes proprietary medical devices and employs about 7,600 people with over 800 sales and clinical support staff worldwide.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MMSI
+0.16%
+0.16%Session close to close
In the Apr 6 session, MMSI gained 0.16%, reflecting a mild positive market reaction.
This announcement schedules Merit Medical’s Q1 2026 results for release after market close on April ...
Analysis
This announcement schedules Merit Medical’s Q1 2026 results for release after market close on April 30, 2026, followed by an investor conference call at 4:30 p.m. Eastern. It adds a clear near-term catalyst after recent acquisitions, product launches, and guidance updates. Investors may focus on how Q1 performance tracks against the previously issued 2026 revenue and EPS guidance and integration of recent strategic moves.
Key Figures
Earnings release date:April 30, 2026Quarter end date:March 31, 2026Conference call time:4:30 p.m. Eastern+4 more
7 metrics
Earnings release dateApril 30, 2026Q1 2026 results release after market close
Quarter end dateMarch 31, 2026Quarter for upcoming earnings report
Conference call time4:30 p.m. EasternInvestor call on April 30, 2026
Call regional times3:30 p.m. Central / 2:30 p.m. Mountain / 1:30 p.m. PacificInvestor conference call time zones
Founded1987Year Merit Medical was founded
Sales & clinical team800+ individualsDomestic and international sales and clinical support force
New board chair and strong preliminary Q4 2025 revenue growth guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news—including acquisitions, product launches, partnerships, and earnings—has consistently been followed by negative next-day price reactions, suggesting a pattern of selling into news.
Recent Company History
This announcement schedules the Q1 2026 earnings release after a series of significant updates. Since January 2026, MMSI reported strong Q4 and full-year 2025 results with raised 2026 guidance, launched the Resilience esophageal stent, entered a ViaVerte distribution agreement with Medtronic, and acquired View Point Medical for about $140 million. Despite generally positive fundamentals and growth initiatives, each of these events was followed by a negative 24-hour price reaction, framing expectations around the upcoming earnings date.
Key Terms
cardiology, radiology, oncology, endoscopy
4 terms
cardiologymedical
"particularly in cardiology, radiology, oncology, critical care, and endoscopy."
Cardiology is the medical specialty that diagnoses and treats the heart and blood vessels, ranging from routine checkups to interventions for heart attacks and chronic heart failure. Investors watch cardiology because advances in treatments, devices, tests or guidelines can change demand, costs and regulatory risk for drugmakers, device makers and hospitals — like a car mechanic’s new tool changing which repair shops get business and how much they can charge.
radiologymedical
"particularly in cardiology, radiology, oncology, critical care, and endoscopy."
Radiology is the medical field that uses imaging tools — like X-rays, CT scans, MRIs and ultrasound — to look inside the body and diagnose or monitor illnesses. For investors, radiology matters because it drives demand for hospital services, diagnostic equipment, software and imaging-based drug trials, acting like a camera and map that guides treatment decisions and revenue across healthcare businesses.
oncologymedical
"particularly in cardiology, radiology, oncology, critical care, and endoscopy."
Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.
endoscopymedical
"particularly in cardiology, radiology, oncology, critical care, and endoscopy."
A medical procedure that uses a thin, flexible tube with a tiny camera and small tools to look inside and sometimes treat organs through natural openings or small cuts — like sending a flashlight and repair kit down a pipe to inspect and fix problems. Investors care because the number of procedures, new device designs, safety records, regulatory approvals and reimbursement rules drive sales and profits for hospitals, equipment makers and suppliers.
SOUTH JORDAN, Utah, April 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2026, after the close of the stock market on Thursday, April 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, April 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).
To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.
A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com.
ABOUT MERIT
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.
Contacts:
PR/Media Inquiries: Sarah Comstock Merit Medical
Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare
When will Merit Medical (MMSI) announce Q1 2026 results and when is the conference call?
Merit will announce Q1 2026 results after market close on April 30, 2026 and hold a call at 4:30 p.m. ET. According to Merit Medical, the call is scheduled for April 30, 2026 at 4:30 p.m. ET with corresponding regional times listed.
How can investors access the Merit Medical (MMSI) April 30, 2026 earnings webcast and slides?
Investors can access a live webcast and slide deck via links posted on the company website. According to Merit Medical, registration links and the webcast will be available at www.merit.com, and registrants receive dial-in confirmation details.
Do I need to pre-register for Merit Medical (MMSI) investor call on April 30, 2026?
Pre-registration is requested to receive dial-in information and confirmation for the call. According to Merit Medical, registrants will receive confirmation with dial-in details and can also join the live webcast without dialing in.
What time zones correspond to the Merit Medical (MMSI) 4:30 p.m. ET earnings call on April 30, 2026?
The 4:30 p.m. ET call corresponds to 3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific on April 30, 2026. According to Merit Medical, these regional times are provided to help investors join from different U.S. time zones.
Where can investors find Merit Medical (MMSI) investor contact information for April 2026 results?
Investor inquiries can be directed to the listed contacts for Merit Medical and its investor relations advisor. According to Merit Medical, contact details including phone numbers and emails are provided for PR and investor inquiries.
What does Merit Medical (MMSI) describe about its business and workforce in April 2026 disclosures?
Merit describes itself as a developer and manufacturer of proprietary medical devices serving interventional and diagnostic specialties. According to Merit Medical, the company employs about 7,600 people and has over 800 sales and clinical support staff worldwide.
